Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A. Torres T, et al. Among authors: carrascosa jm. Am J Clin Dermatol. 2021 Jul;22(4):567-579. doi: 10.1007/s40257-021-00598-4. Epub 2021 Mar 30. Am J Clin Dermatol. 2021. PMID: 33786754
[Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
Puig L, Bordas X, Carrascosa JM, Daudén E, Ferrándiz C, Hernanz JM, López-Estebaranz JL, Moreno JC, Sánchez-Carazo JL, Vanaclocha F, Vázquez-Veiga H; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Puig L, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2009 May;100(4):277-86. Actas Dermosifiliogr. 2009. PMID: 19463230 Spanish.
[Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents].
Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, García-Bustinduy M, Bordas X, Moreno JC, Hernanz JM, Laguarda S, García-Patos V; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Puig L, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2009 Jun;100(5):386-413. Actas Dermosifiliogr. 2009. PMID: 19558918 Spanish.
[Guidelines on the use of methotrexate in psoriasis].
Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sánchez-Regaña M, Daudén E, Vidal D, Alsina M, Muñoz-Santos C, López-Estebaranz JL, Notario J, Ferrandiz C, Vanaclocha F, García-Bustinduy M, Taberner R, Belinchón I, Sánchez-Carazo J, Moreno JC; Grupo de Psoriasis de la AEDV. Carretero G, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2010 Sep;101(7):600-13. Actas Dermosifiliogr. 2010. PMID: 20858386 Spanish.
[Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group].
Carrascosa JM, López-Estebaranz JL, Carretero G, Daudén E, Ferrándiz C, Vidal D, Belinchón I, Sánchez-Regaña M, Puig L; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Carrascosa JM, et al. Actas Dermosifiliogr. 2011 Apr;102(3):175-86. doi: 10.1016/j.ad.2010.11.002. Actas Dermosifiliogr. 2011. PMID: 21310368 Free article. Spanish.
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, Fonseca E, Carretero G, Daudén E, Marrón SE, López-Estebaranz JL, Ferrán M, Sánchez-Regaña M, Muñoz-Santos C, Belinchón I, Puig L; Grupo Español de Psoriasis. Morell L, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2011 Jun;102(5):354-64. doi: 10.1016/j.ad.2010.12.013. Epub 2011 Apr 29. Actas Dermosifiliogr. 2011. PMID: 21530928 Free article. Spanish.
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C. Garcia-Doval I, et al. Among authors: carrascosa jm. Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768. Arch Dermatol. 2012. PMID: 22508869
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: carrascosa jm. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
324 results